Biotechnology

124 articles in this category (Page 3 of 6)

Stock Weather AIBiotechnologyClinical-Stage Pharma

Arcus Biosciences – 2026-01-15 - Increase Confidence 7/10

Negative free cash flow contrasts with analyst optimism and undervaluation thesis, driven by upcoming clinical trial catalysts suggesting near-term upside.

Jan 15, 2026RCUS

Stock Weather AIBiotechnologyClinical Trials

Edgewise Therapeutics – 2026-01-14 - Increase Confidence 8/10

Strong cash position and positive trial data catalyze momentum; stock poised for near-term upside following J.P. Morgan Conference boost.

Jan 14, 2026EWTX

Stock Weather AIBiotechnologyClinical Trials

Viking Therapeutics – 2026-01-14 - increase Confidence 8/10

Negative free cash flow offset by robust cash reserves and recent clinical trial milestones signal imminent upside from VK2735 data catalysts.

Jan 14, 2026VKTX

Stock Weather AIBiotechnologyPrecision Oncology

Erasca – 2026-01-13 - Increase Confidence 6/10

Negative free cash flow and high debt are offset by bullish technicals and a key conference catalyst, pointing to near-term upside.

Jan 13, 2026ERAS

Stock Weather AIBiotechnologyClinical Trials

Structure Therapeutics – 2026-01-13 - Increase Confidence 8/10

Negative free cash flow is offset by strong momentum and recent analyst upgrade, fueling near-term upside potential ahead of clinical data.

Jan 13, 2026GPCR

Stock Weather AIBiotechnologyMomentum Trading

Moderna – 2026-01-13 - Increase Confidence 8/10

Negative free cash flow and high leverage offset by revenue forecast hike and bullish golden cross, triggering short-term upside momentum.

Jan 13, 2026MRNA

Stock Weather AIBiotechnologyRegulatory Risk

Travere Therapeutics – 2026-01-13 - Decrease Confidence 7/10

Negative free cash flow and high debt/equity meet FDA review delay, triggering sell-off; stock likely to decline further near-term.

Jan 13, 2026TVTX

Stock Weather AIBiotechnologyEarnings Catalyst

Adaptive Biotechnologies – 2026-01-12 - Increase Confidence 7/10

Negative free cash flow persists, but accelerating clonoSEQ adoption and improving net loss signal near-term upside ahead of February earnings.

Jan 12, 2026ADPT

Stock Weather AIBiotechnologyGrowth Stocks

Apellis Pharmaceuticals – 2026-01-12 - increase Confidence 8/10

Strong revenue growth and improving losses meet high analyst upside expectations, signaling near-term price momentum for APLS.

Jan 12, 2026APLS

Stock Weather AIBiotechnologyClinical Stage Biotech

Beam Therapeutics – 2026-01-12 - Increase Confidence 8/10

Negative free cash flow offset by $1.25B cash runway and FDA breakthroughs; BEAM-302 & risto-cel catalysts drive near-term upside.

Jan 12, 2026BEAM

Stock Weather AIBiotechnologyClinical Trials

Summit Therapeutics Inc. – 2026-01-12 - increase Confidence 7/10

Negative free cash flow and high leverage are outweighed by strong analyst momentum and Phase III trial expansion, signaling near-term upside.

Jan 12, 2026SMMT

Stock Weather AIBiotechnologyClinical Trials

CG Oncology – 2026-01-09 - Increase Confidence 8/10

Strong cash position and recent positive trial data converge with upcoming J.P. Morgan Conference presentation to catalyze near-term upside.

Jan 9, 2026CGON

Stock Weather AIBiotechnologyHealthcare

Madrigal Pharmaceuticals – 2026-01-09 - Increase Confidence 8/10

Strong revenue growth and recent positive catalysts signal near-term upside despite negative free cash flow.

Jan 9, 2026MDGL

Stock Weather AIBiotechnologyM&A Speculation

NovaBay Pharmaceuticals – 2026-01-09 - increase Confidence 6/10

Negative free cash flow contrasts with potential acquisition catalyst, driving short-term upside in speculative momentum.

Jan 9, 2026NBY

Stock Weather AIBiotechnologyClinical-Stage Stocks

Wave Life Sciences – 2026-01-09 - Increase Confidence 7/10

Negative free cash flow and high debt are offset by strong upcoming catalysts and recent positive trial data, pointing to near-term upside.

Jan 9, 2026WVE

Stock Weather AIBiotechnologyClinical-Stage Pharma

Crinetics Pharmaceuticals – 2026-01-07 - Increase Confidence 7/10

Negative free cash flow and high debt are offset by imminent clinical data readouts and bullish analyst targets, creating near-term catalyst-driven upside potential.

Jan 7, 2026CRNX

Stock Weather AIBiotechnologyClinical-Stage Pharma

Revolution Medicines – 2026-01-07 - increase Confidence 8/10

Strong cash runway and positive trial data for RMC-6236 in pancreatic cancer signal near-term upside despite negative free cash flow.

Jan 7, 2026RVMD

Stock Weather AIBiotechnologyEarnings Catalyst

Liquidia Corporation – 2026-01-02 - increase Confidence 8/10

Profitability achieved in Q3 2025 alongside strong YUTREPIA adoption, with analyst targets implying 40% upside, signals near-term price appreciation.

Jan 2, 2026LQDA

Stock Weather AIBiotechnologyGrowth Stocks

Axsome Therapeutics – 2026-01-01 - Increase Confidence 8/10

Strong revenue growth and imminent NDA submission for AXS-12, combined with recent FDA momentum, signal near-term upside.

Jan 1, 2026AXSM

Stock Weather AIBiotechnologyEarnings Momentum

Corcept Therapeutics – 2026-01-01 - Increase Confidence 7/10

Strong revenue growth and insider option exercises signal confidence, while key clinical data readouts loom—stock poised for near-term upside.

Jan 1, 2026CORT

Stock Weather AIBiotechnologyGrowth Stocks

Axsome Therapeutics – 2025-12-31 - Increase Confidence 7/10

Strong revenue beat and late-stage pipeline momentum outweigh negative cash flow, with next earnings catalyst approaching.

Dec 31, 2025AXSM

Stock Weather AIBiotechnologyEarnings Catalyst

Corcept Therapeutics – 2025-12-31 - Increase Confidence 8/10

Strong free cash flow and gross margin paired with imminent NDA submission for relacorilant drive upside potential in the near term.

Dec 31, 2025CORT

Stock Weather AIBiotechnologyClinical Trials

Corcept Therapeutics – 2025-12-30 - Increase Confidence 8/10

Strong free cash flow and recent FDA acceptance of relacorilant for ovarian cancer signal near-term upside despite high valuation.

Dec 30, 2025CORT

Stock Weather AIBiotechnologyClinical Trials

Ultragenyx Pharmaceutical – 2025-12-30 - Decrease Confidence 8/10

Negative free cash flow and sky-high debt/equity meet Phase III trial failure; stock poised to decrease despite short-term rally.

Dec 30, 2025RARE